OnQuality Pharmaceuticals to Present Two Posters at the 34th EORTC-NCI-AACR Symposium
CID is a potentially life-threatening adverse effect of chemotherapy, often requiring dose reduction or disruption of treatment.
- CID is a potentially life-threatening adverse effect of chemotherapy, often requiring dose reduction or disruption of treatment.
- OnQuality is developing OQL051, a gut-restricted CDK4/6 inhibitor with the potential to prevent CID while minimizing interference with systemically administered chemotherapy regimens.
- The posterat the EORTC-NCI-AACR Symposium will present preclinical toxicology and pharmacology data supporting OQL051's potential as an effective treatment for CID.
- "We're thrilled to present positive preclinical data for two of our programs that address these unmet needs in cancer therapy," said Robert C. Tyler, Ph.D., Senior Medical Director of OnQuality.